Abstract
Original language | English |
---|---|
Pages (from-to) | 1398-1409 |
Number of pages | 12 |
Journal | Mod. Pathol. |
Volume | 33 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- antineoplastic metal complex
- fluorouracil
- programmed death 1 ligand 1
- programmed death 1 receptor
- adenocarcinoma
- adult
- Article
- cancer combination chemotherapy
- cancer surgery
- celiac disease
- cell density
- clinical feature
- cohort analysis
- controlled study
- Crohn disease
- disease association
- female
- human
- human cell
- human tissue
- immunohistochemistry
- longitudinal study
- major clinical study
- male
- microsatellite instability
- middle aged
- prevalence
- priority journal
- protein expression
- retrospective study
- small intestine carcinoma
- tumor associated leukocyte
Fingerprint
Dive into the research topics of 'PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability: Modern Pathology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability : Modern Pathology. / Small bowel adenocarcinomas (SBAs).
In: Mod. Pathol., Vol. 33, No. 7, 2020, p. 1398-1409.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability
T2 - Modern Pathology
AU - Small bowel adenocarcinomas (SBAs)
AU - Giuffrida, P.
AU - Arpa, G.
AU - Grillo, F.
AU - Klersy, C.
AU - Sampietro, G.
AU - Ardizzone, S.
AU - Fociani, P.
AU - Fiocca, R.
AU - Latella, G.
AU - Sessa, F.
AU - D’Errico, A.
AU - Malvi, D.
AU - Mescoli, C.
AU - Rugge, M.
AU - Nesi, G.
AU - Ferrero, S.
AU - Furlan, D.
AU - Poggioli, G.
AU - Rizzello, F.
AU - Macciomei, M.C.
AU - Santini, D.
AU - Volta, U.
AU - De Giorgio, R.
AU - Caio, G.
AU - Calabrò, A.
AU - Ciacci, C.
AU - Rizzo, A.
AU - Martino, M.
AU - Cannizzaro, R.
AU - Canzonieri, V.
AU - Elli, L.
AU - Caprioli, F.
AU - Vecchi, M.
AU - Lenti, M.V.
AU - Oreggia, B.
AU - Orlandi, A.
AU - Perfetti, V.
AU - Quaquarini, E.
AU - Silano, M.
AU - Barresi, V.
AU - Ciccocioppo, R.
AU - Luinetti, O.
AU - Pedrazzoli, P.
AU - Pietrabissa, A.
AU - Viglio, A.
AU - Paulli, M.
AU - Corazza, G.R.
AU - Solcia, E.
AU - Vanoli, A.
AU - Di Sabatino, A.
N1 - Cited By :7 Export Date: 18 February 2021 CODEN: MODPE Correspondence Address: Di Sabatino, A.; Department of Internal Medicine, Italy; email: a.disabatino@smatteo.pv.it Chemicals/CAS: fluorouracil, 51-21-8 Funding details: Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR Funding details: Fondazione IRCCS Policlinico San Matteo Funding text 1: Acknowledgements This work was supported by the Fondazione IRCCS San Matteo Hospital—Italian Ministry of Health (Progetto di Ricerca Corrente 2019 to A.D.S.), the Fondazione IRCCS San Matteo Hospital (to O.L.) and the Italian Ministry of Education, University and Research (MIUR) (to the Department of Molecular Medicine of the University of Pavia under the initiative “Dipartimenti di Eccellenza (2018–2022)”). We thank Professor Francesco P. D’Armiento (Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy), Professor Luigi Coppola (Unit of Pathologic Anatomy, San Filippo Neri Hospital, Rome, Italy), Dr. Antonio Maccioni (Pathology Unit, SS. Trinità Hospital, Cagliari, Italy) and Dr. Paola Migliora (Unit of Pathological Anatomy, Sant’Andrea Hospital, Vercelli, Italy) for providing us some formalin-fixed and paraffin-embedded samples and for taking part in the Small Bowel Cancer Italian Consortium. We thank Dr. Roberta Riboni (Anatomic Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy) for her support in molecular biology tests. References: Halfdanarson, T.R., McWilliams, R.R., Donohue, J.H., Quevedo, J.F., A single-institution experience with 491 cases of small bowel adenocarcinoma (2010) Am J Surg, 199, pp. 797-803; Giuffrida, P., Vanoli, A., Arpa, G., Bonometti, A., Luinetti, O., Solcia, E., Small bowel carcinomas associated with immune-mediated intestinal disorders: the current knowledge (2018) Cancers (Basel), 11, p. 1; Vanoli, A., Di Sabatino, A., Furlan, D., Klersy, C., Grillo, F., Fiocca, R., Small bowel carcinomas in celiac or crohn’s disease: clinico-pathological, molecular, and prognostic features. a study from the small bowel cancer italian consortium (2017) J Crohns Colitis, 11, pp. 942-953; Vanoli, A., Di Sabatino, A., Martino, M., Klersy, C., Grillo, F., Mescoli, C., Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns (2017) Mod Pathol, 30, pp. 1453-1466. , COI: 1:CAS:528:DC%2BC2sXhtFSmsLvM; Diosdado, B., Buffart, T.E., Watkins, R., Carvalho, B., Ylstra, B., Tijssen, M., High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas (2010) Clin Cancer Res, 16, pp. 1391-1401. , COI: 1:CAS:528:DC%2BC3cXisFSisrg%3D; Sharpe, A.H., Pauken, K.E., The diverse functions of the PD1 inhibitory pathway (2018) Nat Rev Immunol, 18, pp. 153-167. , COI: 1:CAS:528:DC%2BC2sXhs1WqsrfP; Chen, C., Zhang, F., Zhou, N., Gu, Y.M., Zhang, Y.T., He, Y.D., Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis (2019) Oncoimmunology, 8; Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., PD-1 blockade in tumors with mismatch-repair deficiency (2015) N Engl J Med, 372, pp. 2509-2520. , COI: 1:CAS:528:DC%2BC2MXhtFyrsbrI; Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) Science, 357, pp. 409-413. , COI: 1:CAS:528:DC%2BC2sXht1aksLnN; Thota, R., Gonzalez, R.S., Berlin, J., Cardin, D.B., Shi, C., Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? (2017) Am J Clin Pathol, 148, pp. 208-214. , COI: 1:CAS:528:DC%2BC1MXjvVantb8%3D; Watari, J., Mitani, S., Ito, C., Tozawa, K., Tomita, T., Oshima, T., Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features (2019) Sci Rep., 9; Noh, B.J., Hong, S.M., Jun, S.Y., Eom, D.W., Prognostic implications of immune classification in a multicenter cohort of patients with small intestinal adenocarcinoma (2020) Pathology, 52, pp. 228-235; Salem, M.E., Puccini, A., Grothey, A., Raghavan, D., Goldberg, R.M., Xiu, J., Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers (2018) Mol Cancer Res, 16, pp. 805-812. , COI: 1:CAS:528:DC%2BC1cXosF2rt7w%3D; Crumley, S., Kurnit, K., Hudgens, C., Fellman, B., Tetzlaff, M.T., Broaddus, R., Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes (2019) Mod Pathol, 32, pp. 396-404. , COI: 1:CAS:528:DC%2BC1cXhvVyht7bL; Lee, L.H., Cavalcanti, M.S., Segal, N.H., Hechtman, J.F., Weiser, M.R., Smith, J.J., Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma (2016) Mod Pathol, 29, pp. 1433-1442. , COI: 1:CAS:528:DC%2BC28XhslOqs7jK; Inaguma, S., Lasota, J., Wang, Z., Felisiak-Golabek, A., Ikeda, H., Miettinen, M., Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas (2017) Mod Pathol, 30, pp. 278-285. , COI: 1:CAS:528:DC%2BC28XhvVehsbnL; De Rosa, S., Sahnane, N., Tibiletti, M.G., Magnoli, F., Vanoli, A., Sessa, F., EBV+ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8+ intratumoral lymphocytes (2018) Cancers (Basel), 10, p. 4; Taube, J.M., Galon, J., Sholl, L.M., Rodig, S.J., Cottrell, T.R., Giraldo, N.A., Implications of the tumor immune microenvironment for staging and therapeutics (2018) Mod Pathol, 31, pp. 214-234. , COI: 1:CAS:528:DC%2BC2sXhvFKiurjP; Di Sabatino, A., Corazza, G.R., Celiac disease (2009) Lancet, 373, pp. 1480-1493; Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J.O., 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management (2017) J Crohns Colitis, 11, pp. 3-25; Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A., (2010) AJCC Cancer Staging Manual, pp. 127-132. , New York, NY, Springer; Chiaravalli, A.M., Feltri, M., Bertolini, V., Bagnoli, E., Furlan, D., Cerutti, R., Intratumor T cells, their activation status and survival in gastric carcinomas characterized for microsatellite instability and Epstein-Barr virus infection (2006) Virchows Arch, 448, pp. 344-353; Kulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer (2019) Arch Pathol Lab Med, 143, pp. 330-337; Wood, S.M., Gill, A.J., Brodsky, A.S., Lu, S., Friedman, K., Karashchuk, G., Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway (2017) Mod Pathol, 30, pp. 123-133. , COI: 1:CAS:528:DC%2BC28Xhs1SlsLvP; Vanoli, A., Di Sabatino, A., Martino, M., Dallera, E., Furlan, D., Mescoli, C., Epstein-Barr virus-positive ileal carcinomas associated with Crohn’s disease (2017) Virchows Arch, 471, pp. 549-552; Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J., Classifying cancers based on T-cell infiltration and PD-L1 (2015) Cancer Res, 75, pp. 2139-2145. , COI: 1:CAS:528:DC%2BC2MXpt1Kksrs%3D; Arpa, G., Grillo, F., Giuffrida, P., Nesi, G., Klersy, C., Mescoli, C., Separation of low versus high grade Crohn’s disease-associated small bowel carcinomas is improved by invasive front prognostic marker analysis (2019) J Crohns Colitis, , Epub ahead of print; Rizzo, F., Vanoli, A., Sahnane, N., Cerutti, R., Trapani, D., Rinaldi, A., Small-bowel carcinomas associated with celiac disease: Transcriptomic profiling shows predominance of microsatellite instability-immune and mesenchymal subtypes (2019) Virchows Arch, , Epub ahead of print; Pedersen, K., Foster, N., Overman, M., Boland, P., Kim, S., Arrambide, K., ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA) (2019) Ann Oncol, , https://doi.org/10.1093/annonc/mdz154.006; Ponce de León, C., Angel López-Casado, M., Lorite, P., Palomeque, T., Isabel Torres, M., Dysregulation of the PD-1/PD-L1 pathway contributes to the pathogenesis of celiac disease (2019) Cell Mol Immunol, 16, pp. 777-779; Ma, F., Zhao, M., Song, Z., Wang, Z., T-bet interferes with PD-1/PD-L1-mediated suppression of CD4(+) T cell inflammation and survival in Crohn’s disease (2019) Clin Exp Pharm Physiol, 46, pp. 798-805. , COI: 1:CAS:528:DC%2BC1MXht1Ojsb7O; Kanai, T., Totsuka, T., Uraushihara, K., Makita, S., Nakamura, T., Koganei, K., Blockade of B7-H1 suppresses the development of chronic intestinal inflammation (2003) J Immunol, 171, pp. 4156-4163. , COI: 1:CAS:528:DC%2BD3sXnvVOktr8%3D; Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study (2019) Oncologist, 24, pp. 327-337; Giuffrida, P., Corazza, G.R., Di Sabatino, A., Old and new lymphocyte players in inflammatory bowel disease (2018) Dig Dis Sci, 63, pp. 277-288. , COI: 1:CAS:528:DC%2BC1cXhs1Cluw%3D%3D; Rosenbaum, M.W., Bledsoe, J.R., Morales-Oyarvide, V., Huynh, T.G., Mino-Kenudson, M., PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes (2016) Mod Pathol, 29, pp. 1104-1112. , COI: 1:CAS:528:DC%2BC28XotlCmu7w%3D; Mantovani, A., Romero, P., Palucka, A.K., Marincola, F.M., Tumor immunity: effector response to tumor and role of the microenvironment (2008) Lancet, 371, pp. 771-783. , COI: 1:CAS:528:DC%2BD1cXislWitr0%3D; Von Rahden, B.H., Langner, C., Brücher, B.L., Stein, H.J., Sarbia, M., No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection (2006) Mol Carcinog, 45, pp. 349-352; Minamoto, T., Mai, M., Watanabe, K., Ooi, A., Kitamura, T., Takahashi, Y., Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor (1990) Cancer, 66, pp. 945-952. , COI: 1:STN:280:DyaK3czlt1Gnsg%3D%3D; Friedman, K., Brodsky, A.S., Lu, S., Wood, S., Gill, A.J., Lombardo, K., Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment (2016) Mod Pathol, 29, pp. 528-541. , COI: 1:CAS:528:DC%2BC28XksVygsLY%3D; Brcic, I., Cathomas, G., Vanoli, A., Jilek, K., Giuffrida, P., Langner, C., Medullary carcinoma of the small bowel (2016) Histopathology, 69, pp. 136-140; Jun, S.Y., Park, E.S., Lee, J.J., Chang, H.K., Jung, E.S., Oh, Y.H., Prognostic significance of stromal and intraepithelial tumor-infiltrating lymphocytes in small intestinal adenocarcinoma (2020) Am J Clin Pathol, 153, pp. 105-118
PY - 2020
Y1 - 2020
N2 - Small bowel adenocarcinomas (SBAs) are often associated with poor prognosis and have limited therapeutic options. Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blockade is an effective treatment in many microsatellite instability-high (MSI-H) solid tumors. We aimed at investigating PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease (CeD), Crohn’s disease (CrD), or sporadic, recruited through the Small Bowel Cancer Italian Consortium. We assessed PD-L1 and PD-1 by immunohistochemistry in a series of 121 surgically resected SBAs, including 34 CeD-SBAs, 49 CrD-SBAs, and 38 sporadic SBAs. PD-L1 and PD-1 expression was correlated with several clinico-pathological features, such as the etiology, microsatellite instability status, and tumor-infiltrating lymphocyte (TIL) density. The prevalence of PD-L1 positivity according to combined positive score (CPS) was 26% in the whole cohort of SBAs, with significantly (p = 0.001) higher percentage (35%) in both CeD-SBAs and CrD-SBAs in comparison with sporadic SBAs (5%). CPS ≥ 1 SBAs were significantly (p = 0.013) more frequent in MSI-H cases (41%) than in non-MSI-H ones (18%); however, 15 CPS ≥ 1 microsatellite stable SBAs were also identified. CPS ≥ 1 SBAs showed higher TIL and PD-1+ immune cell density, more frequently medullary histotype, as well as a better outcome in comparison with CPS < 1 cases. This study demonstrates an increased proportion of PD-L1+ cases in both CeD-SBAs and CrD-SBAs in comparison with sporadic SBAs. In addition, the identification of a subset of PD-L1+ microsatellite stable SBAs supports the need to ascertain additional biomarkers of response to immune checkpoint inhibitors along with MSI-H. © 2020, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
AB - Small bowel adenocarcinomas (SBAs) are often associated with poor prognosis and have limited therapeutic options. Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blockade is an effective treatment in many microsatellite instability-high (MSI-H) solid tumors. We aimed at investigating PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease (CeD), Crohn’s disease (CrD), or sporadic, recruited through the Small Bowel Cancer Italian Consortium. We assessed PD-L1 and PD-1 by immunohistochemistry in a series of 121 surgically resected SBAs, including 34 CeD-SBAs, 49 CrD-SBAs, and 38 sporadic SBAs. PD-L1 and PD-1 expression was correlated with several clinico-pathological features, such as the etiology, microsatellite instability status, and tumor-infiltrating lymphocyte (TIL) density. The prevalence of PD-L1 positivity according to combined positive score (CPS) was 26% in the whole cohort of SBAs, with significantly (p = 0.001) higher percentage (35%) in both CeD-SBAs and CrD-SBAs in comparison with sporadic SBAs (5%). CPS ≥ 1 SBAs were significantly (p = 0.013) more frequent in MSI-H cases (41%) than in non-MSI-H ones (18%); however, 15 CPS ≥ 1 microsatellite stable SBAs were also identified. CPS ≥ 1 SBAs showed higher TIL and PD-1+ immune cell density, more frequently medullary histotype, as well as a better outcome in comparison with CPS < 1 cases. This study demonstrates an increased proportion of PD-L1+ cases in both CeD-SBAs and CrD-SBAs in comparison with sporadic SBAs. In addition, the identification of a subset of PD-L1+ microsatellite stable SBAs supports the need to ascertain additional biomarkers of response to immune checkpoint inhibitors along with MSI-H. © 2020, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
KW - antineoplastic metal complex
KW - fluorouracil
KW - programmed death 1 ligand 1
KW - programmed death 1 receptor
KW - adenocarcinoma
KW - adult
KW - Article
KW - cancer combination chemotherapy
KW - cancer surgery
KW - celiac disease
KW - cell density
KW - clinical feature
KW - cohort analysis
KW - controlled study
KW - Crohn disease
KW - disease association
KW - female
KW - human
KW - human cell
KW - human tissue
KW - immunohistochemistry
KW - longitudinal study
KW - major clinical study
KW - male
KW - microsatellite instability
KW - middle aged
KW - prevalence
KW - priority journal
KW - protein expression
KW - retrospective study
KW - small intestine carcinoma
KW - tumor associated leukocyte
U2 - 10.1038/s41379-020-0497-0
DO - 10.1038/s41379-020-0497-0
M3 - Article
VL - 33
SP - 1398
EP - 1409
JO - Mod. Pathol.
JF - Mod. Pathol.
SN - 0893-3952
IS - 7
ER -